What are Niagen Bioscience, Inc. Common Stock's total assets?

Niagen Bioscience, Inc. Common Stock (NAGE) holds $114.3M in total assets, up 40.6% year over year.

How much debt does Niagen Bioscience, Inc. Common Stock have?

Niagen Bioscience, Inc. Common Stock carries $2.6M in total debt against $82.3M of shareholders' equity, a debt-to-equity ratio of 0.03.

How much cash does Niagen Bioscience, Inc. Common Stock have?

Niagen Bioscience, Inc. Common Stock holds $66.5M in cash and equivalents.

Can Niagen Bioscience, Inc. Common Stock cover its short-term obligations?

Its current ratio is 4.61 — current assets exceed current liabilities.

Where does Niagen Bioscience, Inc. Common Stock's balance sheet data come from?

Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Niagen Bioscience, Inc. Common Stock NAGE Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Cash and cash equivalents	$66.55M+19.7%	$64.79M+45.1%	$64.29M+98.4%	$60.47M+117%	$55.62M+102%
Restricted cash	$152K0.0%	$152K0.0%	$152K0.0%	$152K0.0%	$152K0.0%
Accounts receivable, net	$13.07M+85.3%	$9.74M+25.4%	$8.51M+19.9%	$9.66M—	$7.05M—
Inventories	$24.02M+115%	$20.42M+122%	$18.79M+78.2%	$14.41M—	$11.19M—
Raw materials	$13.52M+537%	$7.47M+887%	$3.68M+47.2%	$2.12M—	$2.12M—
Work in process	$2.18M-56.3%	$3.09M+45.3%	$7.04M+155%	$7.19M—	$5M—
Finished goods	$8.31M+131%	$9.86M+69.7%	$7.64M+60.3%	$4.65M—	$3.59M—
Prepaid expenses and other current assets	$1.49M-37.1%	$1.31M-47.1%	$2.03M-3.2%	$2.14M—	$2.37M—
Assets held for sale	——	——	——	——	——
Total current assets	$105.12M+37.9%	$96.81M+51.0%	$93.62M+79.6%	$86.68M—	$76.22M—
Property and equipment, net	$1.3M-21.6%	$1.32M-23.0%	$1.5M-12.7%	$1.63M—	$1.66M—
Operating lease right-of-use assets	7.7%-0.1%	219,200,000%+46,200,000%	7.8%+1.2%	7.8%—	7.8%—
Intangible assets, net	$5.49M+1,603%	$5.66M+1,477%	$246K-38.0%	$284K—	$322K—
Other non-current assets	$406K-11.4%	$425K+15.5%	$417K+11.5%	$405K—	$458K—
Total assets	$114.33M+40.6%	$106.41M+55.8%	$98.14M+73.6%	$91.53M—	$81.34M—
Accounts payable	$13.28M+24.9%	$10.8M+26.6%	$12.74M+84.6%	$13.68M+68.8%	$10.63M+34.6%
Accrued expenses	$7.62M-15.8%	$7.72M-1.2%	$8.7M-9.3%	$7.38M—	$9.05M—
Accrued compensation	——	——	——	——	——
Deferred revenue	$380K+83.6%	$399K-34.7%	$292K+58.7%	$303K—	$207K—
Operating lease liabilities, current	$1.03M+9.9%	$1M+2.0%	$976K-3.2%	$957K—	$939K—
Contract liabilities	$2.57M-0.3%	$2.67M+3.7%	$2.67M+3.7%	$2.67M—	$2.58M—
Total current liabilities	$22.82M+9.5%	$19.92M+11.0%	$22.71M+28.3%	$22.33M—	$20.84M—
Operating lease liabilities, non-current	$1.54M-40.1%	$1.82M+9.5%	$2.08M+10.9%	$2.33M—	$2.58M—
Operating Lease Liabilities (Total)	$2.58M-26.7%	$2.8M+7.7%	$3.05M+6.0%	$3.29M—	$3.52M—
Total liabilities	$32M+23.1%	$29.87M+34.7%	$27.46M+24.0%	$27.33M—	$25.99M—
Common stock	150M0.0%	150M+194,705%	150M0.0%	150M—	150M—
Additional paid-in capital	$240.46M+3.6%	$240.99M+5.7%	$239.27M+7.1%	$237.36M—	$232.12M—
Retained earnings	-$158.21M+10.5%	-$164.53M+9.6%	-$168.66M+10.8%	-$173.24M—	-$176.85M—
Total stockholders' equity	$82.33M+48.8%	$76.53M+66.0%	$70.68M+106%	$64.2M+109%	$55.35M+91.2%
Total liabilities and stockholders' equity	$114.33M+40.6%	$106.41M+55.8%	$98.14M+73.6%	$91.53M—	$81.34M—
Allowance for Doubtful Accounts	$176K+72.5%	$147K+54.7%	$137K+52.2%	$199K—	$102K—
Allowance for Doubtful Accounts Receivable (Current)	$176K+72.5%	$147K+54.7%	$137K+52.2%	$199K—	$102K—
Prepaid expenses and other	$1.49M-37.1%	$1.31M-47.1%	$2.03M-3.2%	$2.14M—	$2.37M—
Deferred Tax Assets and Other Non-Current Assets	$406K-11.4%	$425K+15.5%	$417K+11.5%	$405K—	$458K—
Net Investment in Lease	$2.02M-24.8%	$2.19M+26.7%	$2.36M+24.3%	$2.53M—	$2.68M—
Other intangible assets—net	$5.49M+1,603%	$5.66M+1,477%	$246K-38.0%	$284K—	$322K—
Operating lease right-of-use assets	$2.02M-24.8%	$2.19M+26.7%	$2.36M+24.3%	$2.53M—	$2.68M—
Other non-current assets	$406K-11.4%	$425K+15.5%	$417K+11.5%	$405K—	$458K—
Property, plant and equipment, net	$1.3M-21.6%	$1.32M-23.0%	$1.5M-12.7%	$1.63M—	$1.66M—
Operating Lease Right-of-Use Assets in Other Assets	$2.02M-24.8%	$2.19M+26.7%	$2.36M+24.3%	$2.53M—	$2.68M—
Software and Technology Licenses, Net	$406K-11.4%	$425K+15.5%	$417K+11.5%	$405K—	$458K—
Accrued Progress Collections and Price Adjustments	$2.57M-0.3%	$2.67M+3.7%	$2.67M+3.7%	$2.67M—	$2.58M—
Other Commercial Liabilities	$7.62M-15.8%	$7.72M-1.2%	$8.7M-9.3%	$7.38M—	$9.05M—
Accrued Liabilities, Current	$7.62M-15.8%	$7.72M-1.2%	$8.7M-9.3%	$7.38M—	$9.05M—
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——	——
Lease Liability Payments - Due Year Four	——	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——	——
Contract Liabilities, Non-Current	$2.57M-0.3%	$2.67M+3.7%	$2.67M+3.7%	$2.67M—	$2.58M—
Deferred Compensation Liability (Non-Current)	——	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——	——
Operating Lease Liability Payments - 2028 (Lessee)	——	——	——	——	——
Deferred revenue, net of current portion	$2.57M-0.3%	$2.67M+3.7%	$2.67M+3.7%	$2.67M—	$2.58M—
Total debt	$2.58M-26.9%	$2.8M+7.2%	$3.06M+5.5%	$3.29M—	$3.52M—
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.00—	$0.00—
Common Stock Shares Issued	79.5M+1.3%	79.7M+3.1%	79.6M+4.8%	79.6M—	78.4M—
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$79K+1.3%	$79K+2.6%	$79K+3.9%	$79K—	$78K—
Share-Based Payment - Unrecognized Cost of Nonvested Awards	——	——	——	——	——
Share Price	——	——	——	——	——
Accounts Receivable, Allowance for Credit Loss	——	——	——	——	——
Allowance for doubtful accounts	$176K+72.5%	$147K+54.7%	$137K+52.2%	$199K—	$102K—
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$0—	$0—
Common stock, shares authorized (in shares)	$150M0.0%	$150M0.0%	$150M0.0%	$150M—	$150M—
Common stock, shares issued (in shares)	$79.46M+1.3%	$79.71M+3.1%	$79.64M+4.8%	$79.59M—	$78.43M—
Common Stock, Shares, Outstanding	$79.46M+1.3%	$79.71M+3.1%	$79.64M+4.8%	$79.59M—	$78.43M—
Deferred Compensation Liability, Classified, Noncurrent	——	——	——	——	——
Deferred Compensation Liability Current And Noncurrent	——	——	——	——	——
Deferred Income Current	$380K+83.6%	$399K-34.7%	$292K+58.7%	$303K—	$207K—
Cost not yet recognized	——	——	——	——	——
Working capital adjustment	——	——	——	——	——
Asset purchase agreement with third party	——	——	——	——	——
Raw materials	$13.52M+537%	$7.47M+887%	$3.68M+47.2%	$2.12M—	$2.12M—
Lessee Operating Lease Liability Payments Due	——	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——	——
Operating Lease Weighted Average Discount Rate Percent	——	——	——	——	——
Purchase Obligation	——	——	——	——	——
Share price (in dollars per share)	——	——	——	——	——
Foreign currency translation impact	-$3K+40.0%	-$9K-125%	-$9K-28.6%	-$4K—	-$5K—
Purchase Obligation	——	——	——	——	——
Remainder of Fiscal Year 2024	——	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Niagen Bioscience, Inc. Common Stock.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Niagen Bioscience, Inc. Common Stock's total assets?: Niagen Bioscience, Inc. Common Stock (NAGE) holds $114.3M in total assets, up 40.6% year over year.
How much debt does Niagen Bioscience, Inc. Common Stock have?: Niagen Bioscience, Inc. Common Stock carries $2.6M in total debt against $82.3M of shareholders' equity, a debt-to-equity ratio of 0.03.
How much cash does Niagen Bioscience, Inc. Common Stock have?: Niagen Bioscience, Inc. Common Stock holds $66.5M in cash and equivalents.
Can Niagen Bioscience, Inc. Common Stock cover its short-term obligations?: Its current ratio is 4.61 — current assets exceed current liabilities.
Where does Niagen Bioscience, Inc. Common Stock's balance sheet data come from?: Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.